Related Experiment Video
Updated: Oct 9, 2025
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities
Alexander T Bauer1, Christian Gorzelanny2, Christoffer Gebhardt2
1Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Dermatology, Venereology and Allergology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Abstract:
Advances in understanding the molecular mechanisms of tumor progression have achieved impressive progress in the treatment of cancer and so-called immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. Indeed, antibody-based drugs blocking immune escape of tumor cells by modulation of T cell responses are increasingly utilized for a wide range of tumor entities. Nonetheless, response rates remain limited, and the development of secondary resistance is a common problem. In addition, by increasing the immune response a variety of severe side effects are provoked. Next to autoimmune responses, activation of the complement system and skin toxicity, an increased incidence for thrombotic complications has been observed associated with an increased mortality rate. Based on this, it can be postulated that the interplay of coagulation with inflammation in the tumor microenvironment is relevant for each step in the tumor life cycle. This review focuses on the coagulation as central player fostering mechanisms associated with tumor progression. Thus, a better understanding of the molecular pathways involved in the complex interaction of circulating tumor cells, the plasmatic coagulation and immune cells may help to improve therapeutic concepts reducing mortality and morbidity associated with cancer.
Insights
Immune checkpoint inhibitors (ICIs) advance cancer treatment but have limited response rates and cause side effects like thrombosis. Understanding coagulation
Area of Science:
- Oncology
- Immunology
- Hematology
Background:
- Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by modulating T cell responses.
- Despite their success, ICIs face challenges including limited response rates, secondary resistance, and severe side effects, notably thrombotic complications.
- The tumor microenvironment involves complex interactions between cancer cells, immune cells, and coagulation factors.
Purpose of the Study:
- To review the central role of coagulation in promoting tumor progression.
- To elucidate the molecular pathways linking coagulation, inflammation, and cancer.
- To highlight the interplay between circulating tumor cells, plasmatic coagulation, and immune cells.
Main Methods:
- Literature review focusing on the intersection of coagulation and cancer biology.
- Analysis of molecular mechanisms underlying tumor progression and immune evasion.
- Examination of the impact of coagulation on tumor cell interactions and immune responses.
Main Results:
- Coagulation is identified as a key factor fostering tumor progression.
- The interplay between coagulation and inflammation in the tumor microenvironment influences cancer development.
- Thrombotic complications are an observed side effect of cancer immunotherapies, increasing mortality.
Conclusions:
- Understanding the molecular pathways of coagulation in cancer is crucial for improving therapeutic strategies.
- Targeting the interaction between coagulation, tumor cells, and immune cells may reduce cancer-associated mortality and morbidity.
- Further research into coagulation's role can lead to more effective and safer cancer treatments.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:17Intracellular Signaling Affects Focal Adhesions
Some...
02:17The Tumor Microenvironment
01:28Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...